What’s new in breast pathology 2022: WHO 5th edition and biomarker updates

Kristen Muller; Julie M. Jorns; Gary Tozbikian

doi:10.4132/jptm.2022.04.25

Journal of Pathology and Translational Medicine (May 2022)

What’s new in breast pathology 2022: WHO 5th edition and biomarker updates

Kristen Muller,
Julie M. Jorns,
Gary Tozbikian

Affiliations

Kristen Muller: Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
Julie M. Jorns: Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
Gary Tozbikian: Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA

DOI: https://doi.org/10.4132/jptm.2022.04.25
Journal volume & issue: Vol. 56, no. 3
pp. 170 – 171

Abstract

Read online

The 5th edition WHO Classification of Breast Tumours (2019) has introduced changes to our practices. Highlights are presented below, with a focus on modifications to morphological subtype categorization. In addition, we summarize important updates to ER and PR testing made in the 2020 ASCO/CAP guidelines, and briefly discuss PD-L1 and Ki-67 testing in breast cancer.

Published in Journal of Pathology and Translational Medicine

ISSN: 2383-7837 (Print); 2383-7845 (Online)
Publisher: Korean Society of Pathologists & the Korean Society for Cytopathology
Country of publisher: Korea, Republic of
LCC subjects: Medicine: Pathology
Website: http://jpatholtm.org/

About the journal